HER2 assessment by silver in situ hybridization: where are we now?

被引:7
作者
Sanguedolce, Francesca [1 ]
Bufo, Pantaleo [1 ]
机构
[1] Univ Hosp, Dept Pathol, I-71121 Foggia, Italy
关键词
breast cancer; bright field in situ hybridization; gastric cancer; HER2; testing; immunohistochemistry; silver in situ hybridization; trastuzumab; GROWTH-FACTOR RECEPTOR; REAL-TIME PCR; METASTATIC BREAST-CANCER; HER-2/NEU GENE AMPLIFICATION; RABBIT MONOCLONAL-ANTIBODIES; REVERSE TRANSCRIPTION-PCR; INVASIVE DUCTAL CARCINOMA; POLYMERASE-CHAIN-REACTION; CORE-NEEDLE BIOPSIES; GASTRIC-CANCER;
D O I
10.1586/14737159.2015.992416
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
HER2 testing in breast and gastric cancer is critical not only as a prognostic tool but also as a predictive marker for response to the humanized monoclonal antibody trastuzumab. Currently, HER2 status is assessed on histological and cytological specimens by conventional validated methods such as immunohistochemistry and FISH, while bright-field in situ hybridization techniques, such as silver in situ hybridization and chromogenic in situ hybridization, may offer performance benefits over FISH. The major points are first, technical issues, advantages and disadvantages relevant to each methods, and their clinical implications and second, the well-known genetic heterogeneity of HER2, and the occurrence of polysomy of chromosome 17. This review aims to summarize the growing body of literature on the accuracy of bright-field in situ techniques, notably silver in situ hybridization, in assessing HER2 status, and to discuss the role of such methods in pathology practice.
引用
收藏
页码:385 / 398
页数:14
相关论文
共 198 条
  • [1] Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes
    Abraham, SC
    Park, SJ
    Lee, JH
    Mugartegui, L
    Wu, TT
    [J]. MODERN PATHOLOGY, 2003, 16 (08) : 786 - 795
  • [2] Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
    Ajani, Jaffer A.
    Rodriguez, Wuilbert
    Bodoky, Gyorgy
    Moiseyenko, Vladimir
    Lichinitser, Mikhail
    Gorbunova, Vera
    Vynnychenko, Ihor
    Garin, August
    Lang, Istvan
    Falcon, Silvia
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1547 - 1553
  • [3] [Anonymous], PATHOL RES INT
  • [4] [Anonymous], 2007, J CLIN ONCOL, DOI DOI 10.1200/JCO.2006.09.2775
  • [5] [Anonymous], ONCOGENE CANC BENCH
  • [6] [Anonymous], BASIC APPL PATHOLOGY
  • [7] [Anonymous], J GASTROINT DIG SYST
  • [8] [Anonymous], 33 ANN SAN ANT BREAS
  • [9] Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
    Arnould, L
    Denoux, Y
    MacGrogan, G
    Penault-Llorca, F
    Fiche, M
    Treilleux, I
    Mathieu, MC
    Vincent-Salomon, A
    Vilain, MO
    Couturier, J
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (10) : 1587 - 1591
  • [10] Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification
    Arnould, Laurent
    Arveux, Patrick
    Couturier, Jerome
    Gelly-Marty, Marion
    Loustalot, Catherine
    Ettore, Francette
    Sagan, Christine
    Antoine, Martine
    Penault-Llorca, Frederique
    Vasseur, Berangere
    Fumoleau, Pierre
    Coudert, Bruno P.
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (21) : 6404 - 6409